On this page
WWOX
WW domain containing oxidoreductase
WWOX is located on the long (q) arm of chromosome 16, at band 16q23.1-q23.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 16 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The WWOX gene encodes WW domain containing oxidoreductase, a protein that functions as a tumour suppressor and participates in fundamental cellular processes including DNA repair, apoptosis regulation, and metabolic coordination. The gene spans one of the most fragile regions of the human genome, making it particularly susceptible to chromosomal alterations. Loss of WWOX function has been implicated in cancer development, whilst pathogenic germline variants cause devastating neurological conditions. WWOX connects cellular stress responses to developmental programmes in the nervous system, bridging oncology and neurogenetics.
What the gene does
WWOX functions as a scaffold protein that coordinates multiple cellular signalling pathways through its WW domains, which recognise and bind specific proline-rich sequences in partner proteins. The protein plays a critical role in maintaining genomic stability by facilitating DNA damage responses and coordinating cell cycle checkpoints. WWOX also regulates metabolic pathways through interactions with enzymes involved in steroid and lipid metabolism. The oxidoreductase domain suggests enzymatic activity, though the precise substrates remain under investigation. In neurons, WWOX appears essential for proper development and function, potentially through regulation of calcium signalling and synaptic activity. The protein shuttles between cellular compartments, including the nucleus and mitochondria, allowing it to integrate signals across multiple organelles and coordinate appropriate cellular responses to stress.
Video: Genetics 101
Chromosome location
WWOX is located on chromosome 16 at band q23.1-q23.2. This genomic region encompasses one of the most common fragile sites in the human genome, designated FRA16D. The large size and fragile nature of this locus means WWOX is vulnerable to chromosomal breaks and deletions. These structural features make the gene frequently disrupted in cancer cells through chromosomal rearrangements.
Protein structure
The WWOX protein comprises 414 amino acids organised into several functional regions. A short disordered region spans amino acids 1-23 at the N-terminus. The protein contains two WW domains: WW 1 (amino acids 16-49) and WW 2 (amino acids 57-90), which mediate protein-protein interactions by recognising proline-rich motifs in binding partners. A nuclear localisation signal occupies amino acids 50-55, directing the protein to the nucleus. The C-terminal half includes a region mediating interaction with MAPT (amino acids 125-414) and a segment responsible for targeting to the mitochondria (amino acids 209-273). This domain architecture allows WWOX to function as a multi-compartment signalling hub.
Key variants
Pathogenic variants in WWOX follow various inheritance patterns depending on the specific alleles involved. Biallelic loss-of-function variants typically cause severe early-onset neurological disease, whilst heterozygous variants may act as cancer predisposition factors. Most disease-causing variants are missense changes or small deletions that disrupt the WW domains or abolish protein stability. The variant spectrum reflects the gene's dual role in neurodevelopment and tumour suppression.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
WWOX-related disorders primarily manifest as severe neurological conditions characterised by early-onset seizures, developmental delay, and progressive neurodegeneration. The most common presentation is epileptic encephalopathy, which typically appears in infancy or early childhood with intractable seizures and profound intellectual disability. The severity and specific features depend on the nature of the variants and whether one or both gene copies are affected. These conditions represent some of the most challenging neurogenetic disorders in clinical practice.
- Epileptic encephalopathy (all DEE) Dedicated page coming soon
UK clinical status
WWOX appears on multiple NHS Genomic Medicine Service gene panels, reflecting its importance in neurogenetics. The gene holds green (high evidence) status on panels including Early onset or syndromic epilepsy (R59), Intellectual disability (R29), and Hereditary ataxia with onset in adulthood (R54). It also features on the DDG2P list and panels for Ataxia and cerebellar anomalies, Fetal anomalies (R21), and Hereditary ataxia. This broad panel representation ensures that WWOX sequencing is available through the NHS for patients presenting with relevant clinical features.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What type of conditions are associated with WWOX variants?
Pathogenic variants in WWOX primarily cause severe neurological disorders, particularly epileptic encephalopathy with early-onset seizures and developmental delay. The protein's role as a tumour suppressor means variants may also contribute to cancer predisposition, though the neurological manifestations are typically the most clinically significant feature.
How common are WWOX-related conditions?
WWOX-related epileptic encephalopathy is rare, though precise prevalence figures are not well established. The condition is recognised internationally and appears on multiple clinical diagnostic panels, suggesting it accounts for a small but important proportion of severe early-onset epilepsy cases.
Why is WWOX considered a fragile gene?
WWOX spans one of the most common fragile sites in the human genome (FRA16D), a chromosomal region prone to breaks and rearrangements. This structural vulnerability means the gene is frequently disrupted in cancer cells and makes it susceptible to large deletions that can cause disease.